CLU/APO J抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P02445(CLU/APO J Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02445(CLU/APO J Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

Clusterin (CLU), also known as apolipoprotein J (APO J), is a multifunctional glycoprotein ubiquitously expressed in human tissues. Initially identified in the 1980s, it gained attention due to its involvement in lipid transport, apoptosis regulation, and stress response. CLU exists as two major isoforms: a secreted heterodimeric glycoprotein (sCLU) formed through proteolytic cleavage, and a nuclear form (nCLU) generated by alternative splicing. sCLU acts as an extracellular chaperone, stabilizing misfolded proteins, inhibiting complement-mediated cell lysis, and promoting cell survival. In contrast, nCLU is pro-apoptotic and linked to tumor suppression.

CLU/APO J antibodies are critical tools for studying its dual roles in physiology and disease. Elevated CLU levels are associated with cancer progression, neurodegenerative disorders (e.g., Alzheimer’s disease), atherosclerosis, and age-related conditions. In cancer, CLU overexpression often correlates with therapy resistance, making it a potential therapeutic target. Antibodies targeting specific CLU epitopes enable detection in immunoassays (Western blot, IHC, ELISA) and functional studies. Commercial CLU antibodies are typically raised against conserved regions (e.g., α-chain or β-chain domains) in hosts like rabbits or mice, with validation for isoform specificity being crucial. Research using these antibodies has advanced understanding of CLU's context-dependent roles, though challenges remain in distinguishing isoforms and clarifying its paradoxical pro-survival versus pro-death mechanisms.